Breast Cancer and the Immune System at MBC Patient Forum 2019

Sara Tolaney, MD, MPH, discusses advances in immunotherapy to treat metastatic breast cancer. Recent trials have tested immunotherapy drugs in tandem with other agents, and early results offer reason for encouragement. One trial found that in patients with metastatic triple-negative breast cancer whose tumor cells carry the PD-L1 receptor, combining an immune checkpoint inhibitor and chemotherapy produced better results than chemotherapy alone, leading to the first FDA approval of an immunotherapy in breast cancer.

Outcomes like this have led investigators to explore whether other chemotherapy agents or immunotherapy drugs might make a more effective pairing. Combinations of immunotherapy drugs and other therapies are being tested in other types of breast cancer as well.

For more information about clinical trials for metastatic breast cancer, please visit https://www.dana-farber.org/metastatic-breast-cancer-program/clinical-research-and-trials/

This information was presented at the EMBRACE Metastatic Breast Cancer Forum at Dana-Farber in October 2019.

EMBRACE (Ending Metastatic Breast Cancer for Everyone) is a Dana-Farber Cancer Institute program designed to offer metastatic breast cancer patients the best care possible by combining our expertise in clinical care and clinical research. As part of the program, our patients are offered a variety of supportive care resources and presented with emerging clinical trial opportunities in a personalized and ongoing basis. If you live a distance away, our care team can also collaborate with you and your local oncologist during your treatment. Near or far, we are here to provide active, continuous care to help you achieve the highest possible quality of life and make informed decisions about your care.

For more information about the EMBRACE Program, please visit https://www.dana-farber.org/metastatic-breast-cancer-program/

Видео Breast Cancer and the Immune System at MBC Patient Forum 2019 канала Dana-Farber Cancer Institute